Immunovant, Inc.
Immunovant, Inc. (IMVT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IMVT · as of Sep 30, 2025
Ownership Breakdown
199
Institutional Holders
▲ 18 vs Q2
$1.53B
Total Inst. Value
▼ $5.53M vs Q2
205.31M
Shares Outstanding
freeFloat 38.40%
95.18M
13F Shares Held
▼ 1.06M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IMVT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC biological products, (no diagnostic substances) | 14.73M | 8.62% | 8.62% | $237.44B | Nov 13, 2025 | ▼ 3.87M |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 9.73M | 5.69% | 5.69% | $156.83B | Nov 14, 2025 | ▲ 228.8K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 6.83M | 4.00% | 4.00% | $110.05B | Nov 7, 2025 | ▼ 199.1K |
ARMISTICE CAPITAL, LLC biological products, (no diagnostic substances) | 5.84M | 3.42% | 3.42% | $94.08B | Nov 17, 2025 | ▲ 636.0K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 5.74M | 3.36% | 3.36% | $92.50B | Nov 12, 2025 | ▼ 110.0K |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 5.46M | 3.19% | 3.19% | $87.98B | Nov 14, 2025 | — held |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 5.16M | 3.02% | 3.02% | $83.25B | Nov 14, 2025 | ▼ 1.71M |
POINT72 ASSET MANAGEMENT, L.P. biological products, (no diagnostic substances) | 3.44M | 2.01% | 2.01% | $55.49B | Nov 14, 2025 | ▲ 105.8K |
STATE STREET CORP biological products, (no diagnostic substances) | 2.89M | 1.69% | 1.69% | $46.63B | Nov 14, 2025 | ▲ 62.5K |
TWO SEAS CAPITAL LP biological products, (no diagnostic substances) | 2.76M | 1.62% | 1.62% | $44.52B | Nov 14, 2025 | ▲ 509.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
28
Increased
+7.79M shares1
New Positions
first time holders16
Decreased
−7.74M shares0
Sold Out
fully exitedNet shares change (top 50)
+48.6K
+7.79M / −7.74M
Net new holders
+13
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IMVT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
28
Buy transactions
22
Sell transactions
1.27
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Fromkin Andrew J. director | May 28, 2026 | Sale | 11,483 | $32.64 | $374.8K | 284.9K | Form 4 ↗ |
Fromkin Andrew J. director | May 28, 2026 | Sale | 210,468 | $33.56 | $7.06M | 74.4K | Form 4 ↗ |
Gloria Melanie Chief Operating Officer | May 20, 2026 | Sale | 249 | $30.41 | $7.6K | 245.0K | Form 4 ↗ |
Gloria Melanie Chief Operating Officer | May 20, 2026 | Sale | 1,168 | $32.15 | $37.6K | 243.8K | Form 4 ↗ |
Gloria Melanie Chief Operating Officer | May 20, 2026 | Sale | 1,698 | $32.95 | $55.9K | 242.1K | Form 4 ↗ |
Pande Atul director | May 20, 2026 | Sale | 6,000 | $32.00 | $192.0K | 116.7K | Form 4 ↗ |
Susman Robert Graham director | May 1, 2026 | Sale | 2,502 | $27.17 | $68.0K | 36.4K | Form 4 ↗ |
Girao Tiago Chief Financial Officer | Apr 23, 2026 | Sale | 25,760 | $29.62 | $763.0K | 247.6K | Form 4 ↗ |
Stout Jay S Chief Technology Officer | Apr 23, 2026 | Sale | 2,754 | $29.62 | $81.6K | 251.7K | Form 4 ↗ |
Van Tuyl Christopher Chief Legal Officer | Apr 8, 2026 | Sale | 5,165 | $24.83 | $128.2K | 183.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Immunovant, Inc. (IMVT) is primarily owned by institutional investors, who hold approximately 46.4% of total shares outstanding. Company insiders own approximately 61.60%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Immunovant, Inc. is FMR LLC, holding approximately 14.73 million shares — equal to 8.62% of outstanding shares — as of September 30, 2025.
A total of 199 institutional investors currently hold IMVT stock, with a combined institutional value of approximately $1.53 billion as of the most recent 13F filing period.
Frequently asked questions
IMVT ownershipImmunovant, Inc. (IMVT) is primarily owned by institutional investors, who hold approximately 46.4% of shares. The largest shareholder is FMR LLC with a 8.62% stake. Company insiders hold 61.60%. Data sourced from SEC Form 13F as of September 30, 2025.